Drug Profile
Tafluprost/timolol - Santen Pharmaceutical
Alternative Names: DE-111; DE-111A; STN-10111; STN-1011101; Tafluprost/timolol maleate; TAPCOM; Tapcom-S; Taptiqom; Timolol maleate/tafluprost; Timolol/tafluprostLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Santen Oy; Santen Pharmaceutical
- Developer AGC Biologics; Asahi Glass; Santen Oy; Santen Pharmaceutical
- Class Amino alcohols; Antiglaucomas; Antihypertensives; Ischaemic heart disorder therapies; Morpholines; Propanolamines; Prostaglandins; Small molecules; Thiadiazoles
- Mechanism of Action Beta-adrenergic receptor antagonists; Prostaglandin F2 alpha agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Glaucoma; Ocular hypertension
Most Recent Events
- 04 Apr 2023 Santen Pharmaceutical completes a phase-III clinical trial in Glaucoma in China (Ophthalmic) (NCT03822559)
- 04 Apr 2023 Santen Pharmaceutical completes a phase-III clinical trial in Ocular hypertension in China (Ophthalmic)(NCT03822559)
- 31 Dec 2022 Preregistration for Glaucoma in China (Ophthalmic) (Santen Pharmaceutical pipeline, July 2023)